《大行》瑞银对中资医药股投资评级及目标价(表)

AASTOCKS
Sep 30, 2025

瑞银发表报告,列出对中资医药股投资评级及目标价表列如下:股份 | 投资评级 | 目标价(港元)恒瑞医药(01276.HK)| 买入 | 97.8元翰森制药(03692.HK)| 买入 | 48.2元中生制药(01177.HK)| 买入 | 12.2元三生制药(01530.HK) | 买入 | 41元石药集团(01093.HK)| 买入-> 中性 | 10元先声药业(02096.HK)| 买入 | ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10